TP53 and B-cell chronic lymphocytic leukemia: The TP53 mutation indicates the most unfavorable prognostic criteria in CLL patients, and recent Bruton ́s tyrosine kinase inhibitors such as Ibrutinib have shown earlier disease progression [703].